Patients with FAMMM (mainly associated with alteration of the CDKN2A gene, involved in cell cycle regulation), clinically characterized by the presence of atypical nevi and a total body nevi count > 50, have a very high risk of melanoma, ranging from 28% to 67%. The gene discussed is CDKN2A; the disease is melanoma.